Cargando…

The Use of Ovarian Vein Sampling to Lateralize a Virilizing Leydig Cell Ovarian Tumor

BACKGROUND/OBJECTIVE: Leydig cell tumors are a rare androgen-secreting ovarian tumor. We present a patient with virilization symptoms secondary to a Leydig cell tumor, with nonrevealing imaging studies, that was localized using ovarian vein sampling (OVS). CASE REPORT: A 56-year-old postmenopausal w...

Descripción completa

Detalles Bibliográficos
Autores principales: Baweja, Kirun, Shuster, Shirley, Awad, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Clinical Endocrinology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690409/
https://www.ncbi.nlm.nih.gov/pubmed/38045790
http://dx.doi.org/10.1016/j.aace.2023.07.003
_version_ 1785152520160542720
author Baweja, Kirun
Shuster, Shirley
Awad, Sara
author_facet Baweja, Kirun
Shuster, Shirley
Awad, Sara
author_sort Baweja, Kirun
collection PubMed
description BACKGROUND/OBJECTIVE: Leydig cell tumors are a rare androgen-secreting ovarian tumor. We present a patient with virilization symptoms secondary to a Leydig cell tumor, with nonrevealing imaging studies, that was localized using ovarian vein sampling (OVS). CASE REPORT: A 56-year-old postmenopausal woman was referred by her gynecologist to the endocrinology clinic for voice-deepening, clitoral enlargement, scalp hair loss, and excessive body hair growth. Her total testosterone was 11.5 (0.3-1.3 nmol/L), bioavailable testosterone was 7.19 (0.1-0.6 nmol/L), and dehydroepiandrosterone sulfate was 4.0 (0.8-4.9 μmol/L). Transvaginal ultrasound and abdominal magnetic resonance imaging showed no adrenal or ovarian masses bilaterally. On adrenal vein sampling (AVS) and OVS, total testosterone from the left gonadal vein was 780.0 (0.3-1.3 nmol/L) and right gonadal vein was 18.6 (0.3-1.3 nmol/L), with a left-to-right ovarian testosterone ratio of 41.94. A bilateral salpingo-oophorectomy was performed, and a 1.0 cm Leydig cell tumor in the left ovary was noted on histopathology. One month after surgery, her total and bioavailable testosterone were <0.4 (0.3-1.3 nmol/L and 0.1-0.6 nmol/L, respectively). At 6 months, she had normalization of her voice to baseline, decreased clitoral size, decreased hair growth on her back, and improvement in her male-pattern baldness. DISCUSSION: OVS and AVS are useful diagnostic investigation tools in cases of virilization, in which imaging is nonrevealing. Our case supports previously suggested left-to-right ovarian vein testosterone ratio of ≥15 being associated with a left-sided tumor. CONCLUSION: Few cases have been published on the interpretation of AVS and OVS in the setting of virilization. Previously suggested ratios for lateralization were valid for this patient.
format Online
Article
Text
id pubmed-10690409
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association of Clinical Endocrinology
record_format MEDLINE/PubMed
spelling pubmed-106904092023-12-02 The Use of Ovarian Vein Sampling to Lateralize a Virilizing Leydig Cell Ovarian Tumor Baweja, Kirun Shuster, Shirley Awad, Sara AACE Clin Case Rep Case Report BACKGROUND/OBJECTIVE: Leydig cell tumors are a rare androgen-secreting ovarian tumor. We present a patient with virilization symptoms secondary to a Leydig cell tumor, with nonrevealing imaging studies, that was localized using ovarian vein sampling (OVS). CASE REPORT: A 56-year-old postmenopausal woman was referred by her gynecologist to the endocrinology clinic for voice-deepening, clitoral enlargement, scalp hair loss, and excessive body hair growth. Her total testosterone was 11.5 (0.3-1.3 nmol/L), bioavailable testosterone was 7.19 (0.1-0.6 nmol/L), and dehydroepiandrosterone sulfate was 4.0 (0.8-4.9 μmol/L). Transvaginal ultrasound and abdominal magnetic resonance imaging showed no adrenal or ovarian masses bilaterally. On adrenal vein sampling (AVS) and OVS, total testosterone from the left gonadal vein was 780.0 (0.3-1.3 nmol/L) and right gonadal vein was 18.6 (0.3-1.3 nmol/L), with a left-to-right ovarian testosterone ratio of 41.94. A bilateral salpingo-oophorectomy was performed, and a 1.0 cm Leydig cell tumor in the left ovary was noted on histopathology. One month after surgery, her total and bioavailable testosterone were <0.4 (0.3-1.3 nmol/L and 0.1-0.6 nmol/L, respectively). At 6 months, she had normalization of her voice to baseline, decreased clitoral size, decreased hair growth on her back, and improvement in her male-pattern baldness. DISCUSSION: OVS and AVS are useful diagnostic investigation tools in cases of virilization, in which imaging is nonrevealing. Our case supports previously suggested left-to-right ovarian vein testosterone ratio of ≥15 being associated with a left-sided tumor. CONCLUSION: Few cases have been published on the interpretation of AVS and OVS in the setting of virilization. Previously suggested ratios for lateralization were valid for this patient. American Association of Clinical Endocrinology 2023-07-22 /pmc/articles/PMC10690409/ /pubmed/38045790 http://dx.doi.org/10.1016/j.aace.2023.07.003 Text en © 2023 AACE. Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Baweja, Kirun
Shuster, Shirley
Awad, Sara
The Use of Ovarian Vein Sampling to Lateralize a Virilizing Leydig Cell Ovarian Tumor
title The Use of Ovarian Vein Sampling to Lateralize a Virilizing Leydig Cell Ovarian Tumor
title_full The Use of Ovarian Vein Sampling to Lateralize a Virilizing Leydig Cell Ovarian Tumor
title_fullStr The Use of Ovarian Vein Sampling to Lateralize a Virilizing Leydig Cell Ovarian Tumor
title_full_unstemmed The Use of Ovarian Vein Sampling to Lateralize a Virilizing Leydig Cell Ovarian Tumor
title_short The Use of Ovarian Vein Sampling to Lateralize a Virilizing Leydig Cell Ovarian Tumor
title_sort use of ovarian vein sampling to lateralize a virilizing leydig cell ovarian tumor
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690409/
https://www.ncbi.nlm.nih.gov/pubmed/38045790
http://dx.doi.org/10.1016/j.aace.2023.07.003
work_keys_str_mv AT bawejakirun theuseofovarianveinsamplingtolateralizeavirilizingleydigcellovariantumor
AT shustershirley theuseofovarianveinsamplingtolateralizeavirilizingleydigcellovariantumor
AT awadsara theuseofovarianveinsamplingtolateralizeavirilizingleydigcellovariantumor
AT bawejakirun useofovarianveinsamplingtolateralizeavirilizingleydigcellovariantumor
AT shustershirley useofovarianveinsamplingtolateralizeavirilizingleydigcellovariantumor
AT awadsara useofovarianveinsamplingtolateralizeavirilizingleydigcellovariantumor